Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673306 | 1.00 | ESR1 (0.39) | ESR1ESR2MEN1TTRALB | |
| SCHEMBL21192755 | 0.83 | ALDH1A1 (0.31) | ESR1ESR2GPR35 | |
| SCHEMBL1423613 | 0.78 | CYP3A4 (0.56) | MEN1TTRALBKMT2ACYP3A4 | |
| SCHEMBL29560065 | 0.78 | TRPV4 (0.39) | ESR1ESR2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL29786557 | 0.78 | ERN1 (0.42) | ESR1ESR2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL4254090 | 0.78 | ERN1 (0.42) | ESR1ESR2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL504867 | 0.78 | TRPV4 (0.39) | ESR1ESR2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL13029 | 0.77 | CYP3A4 (0.50) | ESR1ESR2CYP3A4TSHRTDP1 | |
| SCHEMBL25190108 | 0.75 | CYP11B1 (0.37) | ESR1ESR2CYP11B1CYP11B2TRPV4 | |
| SCHEMBL22119985 | 0.75 | KHK (0.39) | ESR1ESR2CYP11B1CYP11B2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025085527-A1 | 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119698416-A | Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors | 英特莱治疗公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024254537-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1783124-A1 | 2-PHENYLTHIOPHENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | ESR1 1076/4885ESR2 720/4885MEN1 3974/4885 |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | ESR1 4273/4885ESR2 2420/4885MEN1 4831/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | ESR1 4206/4885ESR2 4585/4885MEN1 4809/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | ESR1 3333/4885ESR2 1922/4885MEN1 2543/4885 |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | ESR1 4120/4885ESR2 3443/4885MEN1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.